HomeCompareTALS vs QYLD

TALS vs QYLD: Dividend Comparison 2026

TALS yields 55.51% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TALS wins by $496.2K in total portfolio value
10 years
TALS
TALS
● Live price
55.51%
Share price
$2.72
Annual div
$1.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$521.6K
Annual income
$114,803.66
Full TALS calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — TALS vs QYLD

📍 TALS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTALSQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TALS + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TALS pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TALS
Annual income on $10K today (after 15% tax)
$4,718.75/yr
After 10yr DRIP, annual income (after tax)
$97,583.11/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, TALS beats the other by $92,772.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TALS + QYLD for your $10,000?

TALS: 50%QYLD: 50%
100% QYLD50/50100% TALS
Portfolio after 10yr
$273.5K
Annual income
$60,231.49/yr
Blended yield
22.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TALS right now

TALS
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
5.6
Piotroski
1/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TALS buys
0
QYLD buys
0
No recent congressional trades found for TALS or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTALSQYLD
Forward yield55.51%11.92%
Annual dividend / share$1.51$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$521.6K$25.4K
Annual income after 10y$114,803.66$5,659.31
Total dividends collected$425.9K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TALS vs QYLD ($10,000, DRIP)

YearTALS PortfolioTALS Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$16,251$5,551.47$10,352$1,192.36+$5.9KTALS
2$25,821$8,431.73$10,830$1,347.57+$15.0KTALS
3$40,148$12,520.17$11,460$1,539.07+$28.7KTALS
4$61,153$18,193.88$12,275$1,777.84+$48.9KTALS
5$91,333$25,899.34$13,323$2,078.95+$78.0KTALS
6$133,877$36,150.61$14,667$2,463.34+$119.2KTALS
7$192,771$49,523.37$16,396$2,960.57+$176.4KTALS
8$272,910$66,644.47$18,631$3,612.97+$254.3KTALS
9$380,191$88,177.34$21,548$4,482.15+$358.6KTALS
10$521,608$114,803.66$25,398$5,659.31+$496.2KTALS

TALS vs QYLD: Complete Analysis 2026

TALSStock

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Full TALS Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TALS vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TALS vs SCHDTALS vs JEPITALS vs OTALS vs KOTALS vs MAINTALS vs XYLDTALS vs JEPQTALS vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.